Novo Nordisk's new obesity drug hits 8,000-prescription mark in few weeks: Comparing with Saxenda, it took around four years

Few weeks into its launch, Novo Nordisk's new obesity treatment Wegovy is in high demand in the US, especially compared with the older drug Saxenda. Overall, Novo Nordisk's obesity business has had a strong second quarter, according to report.
Novo Nordisk Executive Vice President, Head of North America Operations, Doug Langa | Photo: Novo Nordisk / PR
Novo Nordisk Executive Vice President, Head of North America Operations, Doug Langa | Photo: Novo Nordisk / PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

Novo Nordisk's new obesity drug Wegovy certainly seems to have gotten off to a great start in the US following its approval from the US Food and Drug Administration (FDA) in early June.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading